Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At Sera Prognostics we strive to provide unparalleled healthcare solutions to preterm babies, helping to ensure the best possible outcome.

We are dedicated to improving the quality of life for preterm infants, providing the best possible care through innovative diagnostics and comprehensive customer support.

Sera Prognostics has earned numerous awards, including the “Most Creative Innovation” award from the International Society for Preterm Birth Research, the “Best Corporate Partner” award from the Healthcare Industry Association, and the “Innovative Technology” award from the American College of Pediatrics.